BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25133419)

  • 1. Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling.
    Walsh CM; Fruman DA
    J Clin Invest; 2014 Sep; 124(9):3688-90. PubMed ID: 25133419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
    Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Burke JE
    Front Immunol; 2018; 9():575. PubMed ID: 29616047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K.
    Lucas CL; Zhang Y; Venida A; Wang Y; Hughes J; McElwee J; Butrick M; Matthews H; Price S; Biancalana M; Wang X; Richards M; Pozos T; Barlan I; Ozen A; Rao VK; Su HC; Lenardo MJ
    J Exp Med; 2014 Dec; 211(13):2537-47. PubMed ID: 25488983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.
    Nguyen T; Lau A; Bier J; Cooke KC; Lenthall H; Ruiz-Diaz S; Avery DT; Brigden H; Zahra D; Sewell WA; Droney L; Okada S; Asano T; Abolhassani H; Chavoshzadeh Z; Abraham RS; Rajapakse N; Klee EW; Church JA; Williams A; Wong M; Burkhart C; Uzel G; Croucher DR; James DE; Ma CS; Brink R; Tangye SG; Deenick EK
    J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36943234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human immunodeficiency caused by mutations in the PIK3R1 gene.
    Deau MC; Heurtier L; Frange P; Suarez F; Bole-Feysot C; Nitschke P; Cavazzana M; Picard C; Durandy A; Fischer A; Kracker S
    J Clin Invest; 2014 Sep; 124(9):3923-8. PubMed ID: 25133428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K pathway defects leading to immunodeficiency and immune dysregulation.
    Nunes-Santos CJ; Uzel G; Rosenzweig SD
    J Allergy Clin Immunol; 2019 May; 143(5):1676-1687. PubMed ID: 31060715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
    Michalovich D; Nejentsev S
    Front Immunol; 2018; 9():369. PubMed ID: 29535736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
    Condliffe AM; Chandra A
    Front Immunol; 2018; 9():338. PubMed ID: 29556229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
    Karanovic D; Michelow IC; Hayward AR; DeRavin SS; Delmonte OM; Grigg ME; Dobbs AK; Niemela JE; Stoddard J; Alhinai Z; Rybak N; Hernandez N; Pittaluga S; Rosenzweig SD; Uzel G; Notarangelo LD
    Front Immunol; 2019; 10():77. PubMed ID: 30891027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review.
    Yang X; Xi R; Bai J; Pan Y
    Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
    Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
    Front Immunol; 2018; 9():568. PubMed ID: 29675019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3Kδ and primary immunodeficiencies.
    Lucas CL; Chandra A; Nejentsev S; Condliffe AM; Okkenhaug K
    Nat Rev Immunol; 2016 Nov; 16(11):702-714. PubMed ID: 27616589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
    Tsujita Y; Mitsui-Sekinaka K; Imai K; Yeh TW; Mitsuiki N; Asano T; Ohnishi H; Kato Z; Sekinaka Y; Zaha K; Kato T; Okano T; Takashima T; Kobayashi K; Kimura M; Kunitsu T; Maruo Y; Kanegane H; Takagi M; Yoshida K; Okuno Y; Muramatsu H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Kojima S; Ogawa S; Ohara O; Okada S; Kobayashi M; Morio T; Nonoyama S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1672-1680.e10. PubMed ID: 27426521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunodeficiency due to a novel variant in PIK3CD: a case report.
    Shashaani N; Chavoshzadeh Z; Ghasemi L; Ghotbabadi SH; Shiari S; Sharafian S; Shiari R
    Pediatr Rheumatol Online J; 2023 Jul; 21(1):71. PubMed ID: 37475052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.
    Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B
    Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variant PIK3R1 Hypermorphic Mutation and Clinical Phenotypes in a Family with Short Statures, Mild Immunodeficiency and Lymphoma.
    Hauck F; Magg T; Krolo A; Bilic I; Hirschmugl T; Laass M; Rösen-Wolff A; Luksch H; Boztug K; Roesler J
    Klin Padiatr; 2017 May; 229(3):113-117. PubMed ID: 28561224
    [No Abstract]   [Full Text] [Related]  

  • 18. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.
    Lucas CL; Kuehn HS; Zhao F; Niemela JE; Deenick EK; Palendira U; Avery DT; Moens L; Cannons JL; Biancalana M; Stoddard J; Ouyang W; Frucht DM; Rao VK; Atkinson TP; Agharahimi A; Hussey AA; Folio LR; Olivier KN; Fleisher TA; Pittaluga S; Holland SM; Cohen JI; Oliveira JB; Tangye SG; Schwartzberg PL; Lenardo MJ; Uzel G
    Nat Immunol; 2014 Jan; 15(1):88-97. PubMed ID: 24165795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
    Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
    Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A
    Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.